ClinicalTrials.gg

Ischemic Stroke clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,623 studies for Ischemic Stroke across more than 10 countries. 981 are recruiting or about to start. 2,127 of them are mainly about Ischemic Stroke (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 3 narrower conditions too, such as Embolic Stroke: 2,665 studies, 992 open.

ClinicalTrials.gov finds 4,093 studies for Ischemic Stroke. How that becomes 2,619 here

This page counts the studies the registry files under Ischemic Stroke, and those it files under no condition that list Ischemic Strokethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 4,093Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −37Filed under a narrower condition, counted on its own pageStroke, Lacunar 14 · Embolic Stroke 14 · Thrombotic Stroke 9
  3. −31List Ischemic Stroke as a condition, but the registry did not file them under itMost often written as “Acute Ischaemic Stroke” (5), “Acute Ischemic Stroke AIS” (5), and “Hemiplegia Following Ischemic Stroke” (4). The registry filed them under other conditions only, most often Stroke (19) and Ischemic Attack, Transient (5).
  4. −1,406Match it another way414 name it in the title, 16 in a keyword, and 976 by a synonym or other text the search reads.
  5. 2,619The count on this page42 of them list Ischemic Stroke in their own words; the registry filed them under no condition.

Status

Completed
1,016
Recruiting
665
Status unknown
343
Not yet recruiting
288
Terminated
127
Active, not recruiting
87

Phase

Phase 2
378
Phase 3
340
Phase 4
152
Phase 1
138
Early Phase 1
14

Where

China
751
United States
480
France
164
Germany
164
Spain
137
Canada
117

Who develops what

Add Ischemic Stroke to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 45 programs from 36 companies, 41 with this as their studies’ main aim; 9 with a live phase 3 study; 12 primary completions in the next 12 months. Compare China Resources Pharmaceutical Group, Jiangsu HengRui Medicine and Regeneron Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Tissue Plasminogen ActivatorRecent, repeated
Evidence
  • NCT05700591 · China Resources Pharmaceutical Group Limited · Phase 3 · comparator · “rt-PA” · registered Jan 2023
  • NCT05295173 · Angde Biotech Pharmaceutical Co., Ltd. · Phase 3 · comparator · “Recombinant human tissue plasminogen activator” · registered Feb 2022
  • NCT03541668 · China Resources Pharmaceutical Group Limited · Phase 3 · comparator · “Alteplase” · registered Mar 2018
  • NCT03151993 · Supergene, LLC · Phase 3 · comparator · “Alteplase” · registered May 2017
  • NCT02572336 · D-Pharm Ltd. · Phase 2 · background · “Tissue Plasminogen Activator (tPA)” · registered Oct 2015
Boehringer Ingelheim28% of its industry studiesUS: Hoffmann-La Roche (FDA 1987)22 studies

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
SHPL-49☆ Track1 live phase-3 study: NCT07241520Shanghai Hutchison Pharmaceuticals Limited
TenecteplaseApproved: EU 2001☆ Track1 live phase-3 study: NCT07201688CSPC Pharmaceutical Group Limited
TenecteplaseApproved: EU 2001☆ Track1 live phase-3 study: NCT07361302Boehringer Ingelheim
Recombinant Human Prourokinase for Injection (rhPro-UK)☆ Track1 live phase-3 study: NCT07942584China Resources Pharmaceutical Group Limited
SIM0811☆ Track1 live phase-3 study: NCT07903701Simcere Pharmaceutical Group Limited

The 5 in phase 3 with the nearest primary completion, of 45 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (12)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 10 Dec 2026 est.LT3001 · Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2 main aimNCT05686642 Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke — primary endpoint: Incidence Adverse Events · 300 enrolled
  • 30 Dec 2026 est.TBO-309 · ThromBio Pty. Ltd. · Phase 2 main aimNCT06813651 Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion — primary endpoint: Proportion of patients achieving a composite outcome of efficacy and safety · 78 enrolled
  • 31 Dec 2026 est.LT3001 · Lumosa Therapeutics Co., Ltd. · Phase 2 main aimNCT05198323 A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT — primary endpoint: The occurrence of symptomatic intracranial hemorrhage within 24 hours after the single dosing; clinical deterioration defined as an change in the NIHSS of 4 points or more and confirmed by MRI · 66 enrolled

9 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Ischemic Stroke studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Thrombolytics 39 open · P2Y12 inhibitors 13 open · Statins 10 open · Factor Xa inhibitors 10 open · NSAIDs 7 open

Coming up

293studies finish main data collection within a year39 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 665 Ischemic Stroke studies recruiting now, 399 (60%) set no upper age limit and 62 (9%) stop at 75 or younger. 27 (4%) take children under 18. 1 (<1%) are for women only and 1 (<1%) for men only; 41 (6%) take healthy volunteers.

Recruiting studies that take each age, of 665
AgeWomenMen
1023 (3%)23 (3%)
18564 (85%)564 (85%)
30608 (91%)608 (91%)
40637 (96%)637 (96%)
50644 (97%)644 (97%)
65648 (97%)648 (97%)
75634 (95%)634 (95%)
85478 (72%)477 (72%)

Across all 2,623 studies, recruiting or not: 11% stop at 75 or younger and 4% at 65; 5% take children; <1% are for women only and <1% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Ischemic Stroke studies take

Of 165 phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 115 mo7–29 · 42 studies——
Phase 1/230 mo20–76 · 27 studies——
Phase 228 mo15–39 · 123 studies24 mo12–35 · 41 studies29 mo15–40 · 82 studies
Phase 2/331 mo26–55 · 31 studies——
Phase 330 mo19–52 · 165 studies—32 mo20–62 · 143 studies
Phase 431 mo24–41 · 85 studies—31 mo24–42 · 76 studies
Interventional, no phase27 mo14–48 · 655 studies24 mo14–46 · 81 studies28 mo14–48 · 574 studies
Observational54 mo24–127 · 441 studies26 mo17–50 · 42 studies57 mo25–140 · 399 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting20

Show 15 more

Newly registered42

Show 37 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,623. Browse all 2,623 → or search them.